|Systematic (IUPAC) name|
|Mol. mass||333.16 g/mol|
Flubromazepam is the name used for a benzodiazepine derivative which was first made in 1960, but was never marketed and did not receive any further attention or study until it started to be sold as a research chemical in late 2012. Its closest relative is phenazepam. Replacing the 2'-Cl with a 2'-F is the single alteration. Flubromazepam is currently being studied. It presumably has sedative, hypnotic, muscle relaxant, and antiepileptic effects common to all benzodiazepine derivatives. A closely related compound, 5-(2-bromophenyl)-7-fluoro-1,3-dihydro-2H-1,4-benzodiazepin-2-one, also appears to have been sold under the same name. Its onset is around 4 hours and reaches its peak at 8 hours.
- US Patent 3136815 - Amino substituted benzophenone oximes and derivatives thereof
- Moosmann B, et al. Characterization of the designer benzodiazepines pyrazolam and flubromazepam and study on their detectability in human serum and urine samples. Institute of Forensic Medicine, Forensic Toxicology, University Medical Center Freiburg, Freiburg, Germany
- US Patent 5317018 - Benzodiazepines and compositions for treating anxiety and panic disorders, and idiopathic and psychomotor epilepsy